Compare MHO & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MHO | RCUS |
|---|---|---|
| Founded | 1976 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.8B |
| IPO Year | 1995 | 2018 |
| Metric | MHO | RCUS |
|---|---|---|
| Price | $121.66 | $22.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $160.00 | $30.27 |
| AVG Volume (30 Days) | 178.2K | ★ 961.1K |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 14.74 | N/A |
| Revenue | ★ $4,417,781,000.00 | $247,000,000.00 |
| Revenue This Year | $0.66 | N/A |
| Revenue Next Year | $6.97 | $70.88 |
| P/E Ratio | $8.25 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $100.22 | $7.06 |
| 52 Week High | $158.92 | $26.40 |
| Indicator | MHO | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 36.85 | 56.62 |
| Support Level | $118.03 | $20.35 |
| Resistance Level | $140.41 | $24.62 |
| Average True Range (ATR) | 3.45 | 1.05 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 30.08 | 85.80 |
M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprises a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.